GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Percheron Therapeutics PER.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.00

+33.33%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Percheron Therapeutics — daily ASX:PER

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Percheron Therapeutics on TradingView ↗
Market value
A$4.3m
Last close × shares
Volume
582.1k
Shares, 9 Nov 2026

About Percheron Therapeutics

Its shares trade on ASX under the ticker PER.AX. It has been listed since 20 December 2001. In the fiscal year to 30 June 2023, it reported revenue of A$384,920 and a net loss of A$11.4m. At that date it held total assets of A$12.8m and shareholders' equity of A$10.0m.

Percheron Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.

Figures and description from our data supplier, not checked against the company's own report.

More about Percheron Therapeutics →

Latest on Percheron Therapeutics

Our reporting

We have not reported on Percheron Therapeutics yet.

Next results

24 Feb 2027

Due on 24 Feb 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Percheron Therapeutics's ticker?

Percheron Therapeutics trades as PER.AX on ASX, under ISIN AU0000317281.

What was Percheron Therapeutics's last closing price?

0.00 on 9 Nov 2026. The figure is in AUD and is never converted.

When does Percheron Therapeutics next report results?

Results are expected on 24 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.